Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4186-4191

  Bröker, Linda E ^a   Valdivieso, Manual ^b   Pilat, Mary Jo ^b   DeLuca, Pamela ^b   Zhou, Xiaofei ^c   Parker, Susan ^c   Giaccone, Giuseppe ^a   LoRusso, Patricia M ^b,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WAYNE STATE UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' TERT BUTYL 3' N TERT BUTYLOXYCARBONYL 4 DEACETYL 3' N DEBENZOYL 3' DEPHENYL 4 O METHOXYCARBONYLPACLITAXEL; ANTINEOPLASTIC AGENT; BMS-275183; BRIDGED COMPOUND; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BODY SURFACE; CHILL; CLINICAL ARTICLE; CLUBBING FINGERS; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EXPOSURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINE RETENTION; VOMITING; DIET RESTRICTION; FAT INTAKE; FOOD; MIDDLE AGED; PHARMACOKINETICS; SOLUBILITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BODY SURFACE AREA; BRIDGED COMPOUNDS; DIETARY FATS; FASTING; FEMALE; FOOD; HUMANS; MALE; MIDDLE AGED; SOLUBILITY; TAXOIDS; THERAPEUTIC EQUIVALENCY;

EID: 48249122764     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4594     Document Type: Article

References (13)

1. Broker LE, deVos FY, van Groeningen CJ, et al. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin Cancer Res 2006; 12:1760-7.
2. Mastalerz H, Cook D, Fairchild CR, et al. The discovery of BMS-275183: an orally efficacious novel taxane. Bioorg Med Chem 2003;11:4315-23.
3. Trump DL, Egorin MJ, Ramesh R, et al. A new oral taxane (BMS-275183): phase I trial with evaluation of pharmacokinetics, pharmacodynamics and bioavailability [abstract]. Proc Am Soc Clin Oncol 2002; 21:398.
4. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590-611.
5. deJongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001;19: 3733-9.
6. de Jong FA, Mathijssen RH, Xie R, Verweij J, Sparreboom A. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004;10: 4068-71.
7. Loos WJ, Gelderblom H, Sparreboom A, Verweij J, de Jonge MJ. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for bodysurface area dosage regimens. Clin Cancer Res 2000;6:2685-9.
8. U.S. Department of Agriculture, Agricultural Research Service. USDA National Nutrient Database for standard reference, release 15. 2002.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2002;92:205-16.
10. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: food-effect bioavailability and fed bioequivalence studies. 2002.
11. Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol 2003;21: 197-202.
12. Bröker LE, Veltkamp SA, Heath El, et al. A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clin Cancer Res 2007;13:3906-12.
13. Marchetti S, Pluim D, VanTellingen O, et al. The novel orally available taxane derivative BMS-275183 is a substrate for P-glycoprotein (PgP MDR1) and MRP2 and interacts with benzimidazole proton pump inhibitors [abstract]. Proc Amer Assoc Cancer Res 2006; 47:1272.